Hormonal
GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to DPP-4 inhibitors in patients with type 2 diabetes, despite a higher incidence of gastrointestinal side effects.
If you have Type 2 Diabetes and are struggling with blood sugar and weight despite taking metformin, switching from a DPP-4 inhibitor (like sitagliptin) to a GLP-1 receptor agonist (like semaglutide or liraglutide) is likely to give you better blood sugar control and more weight loss. Be prepared for some initial stomach upset (nausea), which usually gets better over time. If you strongly dislike injections, ask about oral semaglutide, which offers similar benefits without needles.
These studies have generally demonstrated that the GLP-1 RA provided superior glycemic control and weight loss relative to the DPP-4 inhibitor. Both treatments were associated with a low and comparable incidence of hypoglycemia, but treatment with GLP-1 RAs were invariably associated with a higher incidence of GI adverse events.
Why this rating
Based on a review of multiple head-to-head randomized controlled trials and meta-analyses.
Source
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Matthew P. Gilbert et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00178
More from this paper
- Switching patients from DPP-4 inhibitors to GLP-1 receptor agonists improves glycemic control and weight loss, although it may transiently increase gastrointestinal adverse events.Good
- Combining a GLP-1 receptor agonist with a DPP-4 inhibitor (add-on therapy) provides better glycemic control than switching, without a significant increase in adverse events, contrary to theoretical predictions of antagonism.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →